- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00340990
Immune Responses to Mycobacterium Tuberculosis
Pilot Study of CD4+ T Cell Immune Responses to Mycobacterium Tuberculosis
This study, conducted at the University of Mali in the capital city of Bamako, will investigate how the body reacts to infection with Mycobacterium tuberculosis (MTB), the organism that causes tuberculosis. Tuberculosis is a major global health problem whose solution requires development of an effective vaccine. However, incomplete understanding of how immunity to MTB is acquired and measured limits vaccine development. This study will focus on certain immune system cells - CD4+ T cells - that appear to be very important in fighting tuberculosis.
Individuals 16 years of age and older who have or have not been exposed to either tuberculosis or HIV, or both, may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood tests, review of medical records and laboratory tests, and, if medically indicated, a chest x-ray. Individuals whose medical records indicate a past history of tuberculosis or a positive test for exposure to tuberculosis will have a tuberculin skin test. For this test, a few drops of fluid are placed under the skin to see if the immune system reacts to the substance, indicating previous exposure to MTB.
Participants will come to the University of Mali 10 times over a 1-year period - 7 times within the first 3 months of the study and then once every 3 months until 1 year after enrollment. At each study visit, they will be asked about their medical history and will donate 75 milliliters (about 1/3 cup) of blood, totaling 830 mL over the entire year. More blood may be requested if the participant's immune system reacts strongly to MTB in laboratory tests. No more than 450 mL (2 cups) of blood would be collected every 6 weeks; this amount is the Red Cross limit for regular blood donations every 6 weeks.
The blood samples will be used for tests that measure the level of immunity to tuberculosis. Genetic tests may be performed on blood cells to help interpret special tests of immunity. Because HIV-infected people are included in the study, the findings may also provide information on how HIV renders vulnerability to opportunistic infections, including tuberculosis.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Bamako, Mali
- University of Mali
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
- INCLUSION CRITERIA:
Ability to sign informed consent and willingness to comply with study requirements (including storage of blood specimens for future research on HIV, AIDS, MTB or the immune system).
CATEGORY-SPECIFIC MTB INCLUSION CRITERIA:
Group A (HIV-/MTB[BCG]) HIV ELISA(2) negative; BCG vaccinated with TST(2) less than 15 mm
Group B (HIV+/MTB[BCG]) HIV ELISA/WB(2) positive; BCG vaccinated with TST less than 5 mm
Group C (HIV-/MTB[pulm]) HIV ELISA negative; pulmonary MTB
Group D (HIV-/MTB[diss]) HIV ELISA negative; disseminated MTB
Group E (HIV+/MTB[pulm]) HIV ELISA/WB positive; pulmonary MTB
Group F (HIV+/MTB[diss]) HIV ELISA/WB positive; disseminated MTB
EXCLUSION CRITERIA:
Age less than 18 years (because of the risk for inducing protocol-related anemia)
Hg less than 7.5 g/dL
Latent MTB infection (as evidenced by a TST greater than 5 mm if HIV infected or greater than 15 mm if HIV uninfected) for arms A and B only.
Past history of treated MTB infection
Known or underlying bleeding disorder (due to risk of bleeding from venipuncture)
Psychiatric illness that might interfere with study compliance
Use of immunomodulators (including corticosteroids and IL-2) or cytotoxic agents (including hydroxyurea) within 45 days of signing consent and at any time during study
Small or difficult to access antecubital veins that make venipuncture difficult
Piano di studio
Come è strutturato lo studio?
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Ellner JJ. Review: the immune response in human tuberculosis--implications for tuberculosis control. J Infect Dis. 1997 Nov;176(5):1351-9. doi: 10.1086/514132. No abstract available.
- Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J Infect Dis. 1993 Jun;167(6):1481-97. doi: 10.1093/infdis/167.6.1481.
- Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999 Oct 14;401(6754):708-12. doi: 10.1038/44385.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 999904009
- 04-I-N009
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Mycobacterium tubercolosi
-
François SpertiniUniversity of OxfordCompletatoTubercolosi | Mycobacterium tuberculosis, protezione controSvizzera
-
Serum Institute of India Pvt. Ltd.Vakzine Projekt Management GmbHCompletatoInfezione da Mycobacterium TuberculosisGabon, Kenya, Sud Africa, Tanzania, Uganda
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); WalimuReclutamentoTubercolosi, Polmonare | Infezione da Mycobacterium TuberculosisUganda
-
Shanghai University of Traditional Chinese MedicineHuashan Hospital; Beijing Chest Hospital; China-Japan Friendship Hospital; Shanghai... e altri collaboratoriReclutamentoMalattia Polmonare da Mycobacterium AbscessusCina
-
Bin CaoBeijing Chest Hospital; Shanghai Pulmonary Hospital, Shanghai, China; Anhui Chest... e altri collaboratoriReclutamentoMycobacterium Avium Complex malattia polmonareCina
-
Global Alliance for TB Drug DevelopmentCompletatoTubercolosi | Tubercolosi, Polmonare | Malattia polmonare | Tubercolosi multiresistente ai farmaci | Tubercolosi sensibile ai farmaci | Tubercolosi resistente ai farmaci | Infezione da Mycobacterium TuberculosisStati Uniti
-
Global Alliance for TB Drug DevelopmentCompletatoTubercolosi | Tubercolosi, Polmonare | Malattia polmonare | Tubercolosi multiresistente ai farmaci | Tubercolosi sensibile ai farmaci | Tubercolosi resistente ai farmaci | Infezione da Mycobacterium TuberculosisStati Uniti
-
Oregon Health and Science UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Heart... e altri collaboratoriAttivo, non reclutanteComplesso di Mycobacterium AviumStati Uniti
-
Shanghai Pulmonary Hospital, Shanghai, ChinaKarolinska Institutet; Fudan University; University of Sydney; Shanghai Municipal...ReclutamentoInfezioni batteriche Gram-positive | Infezioni da micobatteri | Infezione da Mycobacterium Avium-Intracellulare | Complesso di Mycobacterium AviumCina
-
Yale UniversityCompletatoInfezione, Mycobacterium Avium-Intracellulare